March 12, 2016

 

endTB aims to find shorter, less toxic and more effective treatments for ‘multidrug-resistant TB’ (MDR-TB) through:

  • access to new drugs
  • two clinical trials
  • advocacy at national and global levels.

Covering 17 countries, the project is a partnership between Partners In Health, Médecins Sans Frontières, Interactive Research & Development and financial partner UNITAID.

Watch the two-minute animation

 

You can contact us, or follow us on Twitter.

Innovative Worldwide Clinical Trial for Multidrug-Resistant Tuberculosis Completes Enrollment

Photo: MDR-TB treatment

 

18 October 2021

Press Release: Innovative Worldwide Clinical Trial for Multidrug-Resistant Tuberculosis Completes Enrollment

Read more

DR-TB Drugs Under the Microscope: 7th edition

MSF Access Campaign

 

27 October 2020

In October 2020, MSF Access Campaign shared the 7th edition of the TB Drugs Under the Microscope: Medicine pricing and patent issues for DR-TB and TB prevention

Read more

PIH MSF MSF UNITAID